AAV Packaging Resource
AAV packaging success depends on plasmid design and quality. Even with a mature process, design flaws, sequence errors, or poor purity can lower titer or cause failure. A well-prepared transfer vector and quality Rep/Cap and helper plasmids are the foundation.
Direct Answer
The most common AAV system uses three plasmids: a transfer vector carrying the genome to be packaged, a Rep/Cap plasmid providing replication and capsid proteins, and a helper plasmid supplying adenoviral helper functions.
The transfer vector's ITRs are the essential cis-acting elements; without complete ITRs the genome cannot replicate or package. Rep/Cap and helper act in trans through AAV production.
The key principle: ITR integrity is non-negotiable; everything else depends on correct sequence and high-quality DNA.
Two ITRs flank the promoter, GOI, optional reporter, optional WPRE, and polyA.
Rep drives DNA replication; Cap forms the VP1/VP2/VP3 capsid and sets the serotype.
E2A, E4, and VA RNA support replication but are not packaged into particles.
Transfer Vector Requirements
ITR integrity, cassette size, sequence stability, and promoter choice each shape packaging efficiency.
| Requirement | Why It Matters | What to Do |
|---|---|---|
| ITR integrity | Essential for replication and packaging | Use Stbl2/3 or NEB Stable; minimize passages; verify by digestion, PCR, or sequencing |
| Cassette size | Capacity is ~4.7 kb including both ITRs | Count promoter + GOI + WPRE + polyA + ITRs; use dual vectors for oversized genes |
| Sequence stability | Repeats, high GC, and palindromes reduce stability | Avoid long repeats and strong secondary structure; consider codon optimization |
| Promoter choice | Sets level, specificity, and durability | Match CMV, CAG, EF1α, hSyn, GFAP, or liver promoters to the target tissue |
For large cassettes, large gene delivery strategies and self-complementary AAV require careful capacity budgeting.
Plasmid DNA Quality
Rep/Cap and helper plasmids should be sequence-correct, pure, low-endotoxin, and predominantly supercoiled.
| Check | Recommended Value | Why It Matters |
|---|---|---|
| Concentration | ≥500 ng/µL (per experiment) | Supports the transfection system |
| OD260/280 | 1.8–2.0 | Low protein contamination |
| OD260/230 | >2.0 | Low salt or organic contamination |
| Gel electrophoresis | Intact band, no degradation | Confirms integrity and absence of extra bands |
| Sequencing | GOI and junctions correct | Confirms the payload and splice junctions |
| ITR verification | Complete, no deletion or rearrangement | ITR problems cause packaging failure |
| Endotoxin | As low as possible; endotoxin-free preferred | Protects HEK293 cell state and transfection |
| Supercoil ratio | ≥80% recommended | Supercoiled DNA transfects and expresses better |
Rep/Cap & Helper
A wrong Cap sequence produces the wrong serotype. The capsid sets tropism, though actual in vivo tropism also depends on route and species.
AAV2, 5, 8, and 9 map to Cap2, Cap5, Cap8, and Cap9; engineered and chimeric capsids extend the range.
Confirm the Rep and Cap regions match the intended serotype before packaging.
Deletion or rearrangement during propagation.
Exceeding capacity lowers titer and truncates genomes.
High endotoxin, low supercoil, or contamination.
Before Transfection
A plasmid can pass its individual purity checks while the combined production set still contains a mismatched serotype, outdated transfer construct, or undocumented substitution. Close these gaps before committing cells and reagents to an AAV packaging run.
| Handoff decision | Evidence to reconcile | Hold the run when |
|---|---|---|
| Match identities | Record the transfer, Rep/Cap, and helper plasmid names, map versions, sequence confirmations, and lot numbers in one run sheet. | A label, map, or Cap assignment disagrees with the intended construct or serotype. |
| Confirm the packaged genome | Check both ITRs using a method suited to their structured sequence, reconcile the intervening cassette length, and retain the source sequence record. | An ITR result is unresolved, or the cassette exceeds the capacity assumed in the study design. |
| Normalize the input | Use the measured concentration and recorded plasmid sizes to calculate the agreed mass or molar input for each component. | A different plasmid size, concentration, or ratio has been used without recalculation and documentation. |
| Review material fitness | Confirm lot-specific purity, topology, endotoxin result, storage history, and any freeze–thaw exposure against the requirements of the process. | Material quality is out of the predefined range or a material change lacks a documented disposition. |
The values in the preceding quality table are planning examples; set release thresholds for the transfection process and intended use rather than treating one universal number as a guarantee of yield.
From Choice to Vector
Creative Biolabs can help you design, verify, and package AAV from well-prepared plasmids.
Design the transfer plasmid around the complete sequence between the ITRs, including promoter, transgene, regulatory elements, and the correct genome format. Review cassette length and ITR integrity before plasmid preparation so an otherwise correct construct does not enter a packaging run with a hidden structural defect.
Bring the transfer, Rep/Cap, and helper plasmids together as one documented production set. Confirm construct identities, lot-specific DNA quality, and a process-appropriate input ratio before transfection; record any plasmid substitution so a change in vector yield can be traced to the materials used.
Match the promoter and expression cassette to the intended cell type and readout, then check that the full design remains within the chosen AAV format’s packaging capacity. Flag sequence features that may complicate plasmid propagation or downstream interpretation before production is scheduled.
Choose the intended natural or engineered capsid and verify the corresponding Cap identity in the production construct. Align that selection with the target tissue and delivery route, while treating predicted tropism as a hypothesis to confirm in the relevant study model.
Measure packaged vector genomes using a defined assay target and report the result with dilution, units, and lot identity. When a low titer or an unexpected assay difference appears, compare the result with plasmid identity, ITR status, input records, and complementary product-quality measurements.
Selected Reading
Buck TM, Wijnholds J. Recombinant adeno-associated viral vectors (rAAV)—vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays. International Journal of Molecular Sciences. 2020;21(12):4197. https://doi.org/10.3390/ijms21124197.
Radukic MT, Le DT, Krassuski T, et al. Degradation and stable maintenance of adeno-associated virus inverted terminal repeats in E. coli. Nucleic Acids Research. 2025;53(2):gkae1170. https://doi.org/10.1093/nar/gkae1170.
Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Molecular Therapy. 2010;18(1):80–86. https://doi.org/10.1038/mt.2009.255.
FAQ
Share your GOI, serotype, and target tissue. We can help you design, verify, and package AAV from well-prepared plasmids.
Tell us about your AAV project and the decision the data must support. Our scientific team will follow up with a project-specific approach.
Inquiry NowFor research use only. Not intended for any clinical use.
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
